 |
JOURNAL TOOLS |
| Opzioni di pubblicazione |
| eTOC |
| Per abbonarsi |
| Sottometti un articolo |
| Segnala alla tua biblioteca |
ARTICLE TOOLS |
| Estratti |
| Permessi |
| Per citare questo articolo |
| Share |
I TUOI DATI
I TUOI ORDINI
CESTINO ACQUISTI
N. prodotti: 0
Totale ordine: € 0,00
COME ORDINARE
I TUOI ABBONAMENTI
I TUOI ARTICOLI
I TUOI EBOOK
COUPON
ACCESSIBILITÀ
REVIEW
Minerva Cardioangiologica 2015 June;63(3):205-16
Copyright © 2015 EDIZIONI MINERVA MEDICA
lingua: Inglese
Transcatheter Aortic Valve Implantation Experience with SAPIEN 3
Ohno Y. 1, 2, Tamburino C. 1, 3, Barbanti M. 1 ✉
1 Department of Cardiology, Ferrarotto Hospital, University of Catania, Catania, Italy; 2 Department of Cardiology, University of Tokai School of Medicine, Isehara, Japan; 3 Excellence Through Newest Advances (ETNA) Foundation, Catania, Italy
Based on randomized trials with first generation devices, transcatheter aortic valve replacement (TAVI) has been included into the treatment strategy for high-risk and inoperable patients with severe aortic stenosis. Procedural complications remain a concern with TAVI, including stroke, vascular complications, paravalvular leak (PVL) and conduction disturbances. Addressing these limitations will support TAVI use in lower risk populations. This review discussed features and most recent clinical evidence of the new balloon-expandable THV (SAPIEN 3, Edwards Lifescience, Irvine, CA, USA).